PMID- 33419185
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210218
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Jan 6
TI  - Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: 
      Focused on IgE-Mediated Pathways.
LID - 10.3390/diagnostics11010083 [doi]
LID - 83
AB  - Despite the expansion of the understanding in asthma pathophysiology and the 
      continual advances in disease management, a small subgroup of patients remains 
      partially controlled or refractory to standard treatments. Upon the 
      identification of immunoglobulin E (IgE) and other inflammatory mediators, 
      investigations and developments of targeted agents have thrived. Omalizumab is a 
      humanized monoclonal antibody that specifically targets the circulating IgE, 
      which in turn impedes and reduces subsequent releases of the proinflammatory 
      mediators. In the past decade, omalizumab has been proven to be efficacious and 
      well-tolerated in the treatment of moderate-to-severe asthma in both trials and 
      real-life studies, most notably in reducing exacerbation rates and corticosteroid 
      use. While growing evidence has demonstrated that omalizumab may be potentially 
      beneficial in treating other allergic diseases, its indication remains confined 
      to treating severe allergic asthma and chronic idiopathic urticaria. Future 
      efforts may be bestowed on determining the optimal length of omalizumab 
      treatment, seeking biomarkers that could better predict treatment response and as 
      well as extending its indications.
FAU - Cheng, Shih-Lung
AU  - Cheng SL
AD  - Department of Internal Medicine, Far Eastern Memorial Taipei Hospital, Department 
      of Chemical Engineering and Materials Science, Yuan Ze University, Zhongli, 
      Taoyuan 32056, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210106
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC7825545
OTO - NOTNLM
OT  - IgE
OT  - airway remodeling
OT  - asthma
COIS- The author declare no conflict of interest.
EDAT- 2021/01/10 06:00
MHDA- 2021/01/10 06:01
PMCR- 2021/01/06
CRDT- 2021/01/09 01:02
PHST- 2020/12/22 00:00 [received]
PHST- 2021/01/02 00:00 [revised]
PHST- 2021/01/04 00:00 [accepted]
PHST- 2021/01/09 01:02 [entrez]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/01/10 06:01 [medline]
PHST- 2021/01/06 00:00 [pmc-release]
AID - diagnostics11010083 [pii]
AID - diagnostics-11-00083 [pii]
AID - 10.3390/diagnostics11010083 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2021 Jan 6;11(1):83. doi: 10.3390/diagnostics11010083.